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Abstract
Pancreas transplantation (PTX) has been demonstrated to restore long-term glucose homeostasis beyond what can
be achieved by intensive insulin therapy or islet transplants. Moreover, PTX has been shown to decrease the
progression of the chronic complications of diabetes. However, PTX patients require chronic use of immunosuppressive
drugs with potential side effects. The long-term follow-up of PTX patients demands special care regarding metabolic
deviations, infectious complications, and chronic rejection. Diabetes and other endocrine metabolic abnormalities
following transplantation are common and can increase morbidity and mortality. Previous recipient-related and
donor-related factors, as well as other aspects inherent to the transplant, act together in the pathogenesis of those
abnormalities. Early recognition of these disturbances is the key to timely treatment; however, adequate tools to achieve
this goal are often lacking. In a way, the type of PTX procedure, whether simultaneous pancreas kidney or not, seems to
differentially influence the evolution of endocrine and metabolic abnormalities. Further studies are needed to define the
best approach for PTX patients. This review will focus on the most common endocrine metabolic disorders seen in the
long-term management of PTX: diabetes mellitus, hyperlipidemia, and bone loss. The authors here cover each one of
these endocrine topics by showing the evaluation as well as proper management in the follow-up after PTX.
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Background
During the past decades, pancreas transplantation (PTX)
has evolved into a procedure mainly reserved for type 1
diabetes patients undergoing simultaneously kidney
transplantation, although it has also been performed as
an isolate procedure [1]. Importantly, it has significantly
improved diabetes related quality of life as well as life
expectancy when compared to kidney only recipients
[2]. However, there is a paucity of publications as related
to the endocrine follow-up evaluation and management
to this population of diabetic patients after pancreas
transplantation.
A Pubmed search was conducted searching for terms
“pancreas transplantation AND metabolism”, “pancreas
transplantation AND diabetes”, “pancreas transplant-
ation AND hyperlipidemia”, “pancreas transplantation
AND bone disease”. We have included only English writ-
ten articles, and we have tried to prioritize prospective
studies. However, due to the lack of available data con-
cerning pancreas transplantation and metabolic abnor-
malities, we have also included retrospective, transversal
and case reports studies.
Main text
PTX is the implantation of a healthy pancreas (usually
from a deceased donor) into a patient who typically has
type 1 diabetes. More than 35,000 PTXs have been re-
ported worldwide [3]. Eighty-four percent of PTX proce-
dures are performed along with kidney transplantation
(both organs coming from the same donor) in diabetic
patients with renal failure. This is referred to as simul-
taneous pancreas-kidney (SPK) transplantation. Nine
percent of PTXs are performed after a previous success-
ful kidney transplantation, which is termed pancreas-
after-kidney transplantation (PAK). The remaining 7 %
of cases are performed as pancreas transplantation alone
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(PTA) in nonuremic patients with very labile difficult to
manage diabetes.
The number of US PTX has declined by over 20 %,
while the overall number of pancreas transplants per-
formed outside the US has increased since 2010. The de-
cline in US numbers is predominantly due to the decline
in PTA and PAK. With the decline in the number of
transplants, a change towards better pancreas donor se-
lection has been observed [3]. Furthermore, the number
of PTX in patients with type 2 diabetes and end-stage
renal disease has increased, and accounted for 9 % of all
SPK recipients in 2010–14 [3].
Pancreas transplantation is superior to intensive insu-
lin therapy with respect to glycated hemoglobin (A1C)
normalization and shows the additional physiological
property of proinsulin and C-peptide release [4]. With
new advances in immunosuppression and changes in
surgical techniques, patient survival and pancreas graft
function have been improving, with PTX being widely
employed as a treatment modality for patients with dia-
betes,especially those with established nephropathy
[1, 3]. Nevertheless, PTX remains a complex procedure,
which is still associated with high general surgical mor-
bidity. In addition, graft failure, side effects of immuno-
suppressive agents, opportunistic infections, and cardio-
and cerebrovascular problems can increase morbidity
and mortality following transplantation [1, 5, 6].
Diabetes and other metabolic abnormalities have fre-
quently been observed after PTX, which can influence
its long-term outcomes. These disorders have been re-
lated to various factors such as immunosuppressive drug
side effects, chronic rejection, and recipient lifestyle after
transplantation. Early recognition of these abnormalities
can provide for more opportune treatment [1, 4, 5].
This review will focus on the most common endocrine
and metabolic disorders related to PTX, such as diabetes,
hyperlipidemia, and bone loss. It is noteworthy to mention
that due to the absence of clinical guidelines developed
through the GRADE approach to this population, our sug-
gested evaluation and follow-up may eventually show vari-
ations from other centers, although we have tried to
summarize them through the best available sources.
Diabetes after pancreas transplantation
Glucose metabolism disorders
No other insulin delivery regimen can achieve the level
of physiologic glycemic regulation than that obtained
with PTX. It has proved more effective in lowering
A1C than intensive insulin treatment or islet trans-
plants [1, 5–7]. Restoration of β‑cell secretory capacity,
improvement in glucose counter-regulation, and return
to hypoglycemia awareness can all be achieved with a
successful PTX [8]. Normalization of A1C occurs
within weeks to months and can last for more than
15 years [9]. Transient hyperglycemia may occur within
the first six months due to acute or chronic rejection, pan-
creatitis, or a marked increase in insulin resistance due to
weight gain. Immunosuppressant medication effects [5, 6],
such as steroids, calcineurin inhibitors (tacrolimus, in par-
ticular), sirolimus, and mycophenolate have also been
linked to posttransplantation hyperglycemia [10].
Hypoglycemia may also occur following PTX [11, 12];
however, severe episodes (with or without symptom
awareness) are rare. By 3 months after PTX, gluca-
gon secretion and hepatic glucose production in re-
sponse to hypoglycemia also return to normal [13].
Although epinephrine and growth hormone responses
to hypoglycemia improve after pancreas transplant,
these do not return to normal [14].
Hyperinsulinism is frequently observed after PTX, as
are elevated C-peptide and proinsulin concentrations.
One likely explanation for these abnormalities—among
other reasons, such as the side effects of immunosup-
pression—is the systemic release of insulin via the iliac
vein, as there is no first-pass effect of insulin through
the liver [15]. It has been reported that drainage of the
venous effluent of the pancreas transplant via the super-
ior mesenteric or portal vein (portal venous drainage) al-
lows comparable blood glucose control but lower insulin
levels, as well as possible advantages in metabolic con-
trol over systemic venous drainage. However, this mech-
anism has not been accepted by all authors [16, 17].
Interestingly, a recent report [18] in SPK patients at 1
and 5 years posttransplantation showed that peripheral
insulin resistance with homeostatic model assessment
(HOMA-IR) >4 was related to decreased pancreatic graft
survival. However, data from HOMA-IR in transplanted
patients is lacking and needs to be interpreted cautiously.
The prevalence of diabetes after pancreas transplant-
ation is variable, depending on the frequency of assess-
ment, duration of follow-up, and, most importantly, the
case definition for diabetes or glucose intolerance. The
estimates of this prevalence is rather imprecise as some
have taken insulin use as the definition for diabetes
while others excluded technical failures or acute rejec-
tion to this assessment.
Hyperglycemia after PTX may have more than one of
the following explanations: graft failure (due to rejection,
thrombosis, or pancreatitis), new-onset diabetes (type 2
or secondary to corticosteroids or immunosuppressive
drugs), immunosuppressant-induced islet cell toxicity
(particularly tacrolimus in high doses), or recurrent
autoimmune type 1 diabetes [19].
Interestingly, the recurrence of type 1 diabetes has
been related to the presence of the autoantibodies to the
zinc transporter 8 and cannot be explained by genetically
encoded amino acid sequence donor-recipient mis-
matches for this autoantigen [20].
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Most cases of late hyperglycemia are attributed to
chronic rejection, which, along with technical failure, is
the most common cause of hyperglycemia following
PTX. Chronic rejection accounts for approximately 50 %
(or more) of the grafts that survive over five years [21].
Pancreas failure in the long term can be related to the
donor, to the surgical manipulation of the graft, or to
the recipient (Table 1).
Neidlinger et al. [22] analyzed 674 PTX recipients over
a 10-year period, with mean follow-up of more than
6 years. The incidence of posttransplant diabetes melli-
tus (PTDM) was 14 % and 25 % at 3 and 10 years after
PTX, respectively. Higher recipient body mass index and
posttransplant weight gain, donor age, and donor-
positive with recipient-negative CMV status were associ-
ated with PTDM after controlling for possible confound-
ing factors [22]. Dean et al. also found a relationship
between PTDM, high pretransplant insulin requirements
and episodes of acute rejection [6]. Hilling et al. demon-
strated that recipient factors are more important in
explaining differences in pancreas graft survival than
donor factors [23]. Interestingly, the incidence of post-
transplant diabetes after successful PTX is lower than
that for other solid organ transplants despite the use of
the same immunosuppressive drugs [24].
Both PAK and PTA entail higher incidence of graft
loss from chronic rejection compared with SPK [3]. For
the PAK and PTA categories, such risk remains high
even after 1 year posttransplantation, thus requiring
greater doses of immunosuppressive drugs and increas-
ing toxicity risks [25]. In one study developed by our
group comparing long-term follow-up between PTA and
SPK patients, we showed that PTA patients exhibited
higher tacrolimus levels and worse renal function [26].
Evaluation
Fasting glucose and A1C should be ordered at all con-
sultations. If A1C is elevated or fasting glucose exceeds
100 mg/dl, unassociated with a recent rejection episode,
an oral glucose tolerance test (OGTT) should be per-
formed [27].
There are no specific criteria to diagnose diabetes
after pancreas transplantation and so it is recom-
mended to adopt the Second International Consensus
of Post -Transplant Diabetes Mellitus [28]. The thresh-
old to define diabetes is based on data from non-
transplant patients: fasting glucose ≥ 126 mg/dl on
more than one occasion, random glucose ≥200 mg/dl
with symptoms or a 2-h glucose level after a 75-g oral
glucose tolerance test ≥200 mg/dl [27]. Although
A1C ≥ 6.5 % can be used to diagnose diabetes in the
general population, it should not be used alone in post-
transplant diabetes mellitus, particularly in the first
year after transplantation [28].
Pancreas transplantation recipients presenting with re-
current hyperglycemia should have their C-peptide levels
measured and undergo pancreas biopsy to distinguish
between rejection, recurrence of type 1 diabetes, and on-
set of type 2 diabetes [4]. Duplex sonographic scanning
of the allograft could be helpful in excluding thrombosis
and rejection. However, sonography is less accurate than
biopsy to diagnose rejection [29, 30]. Ultrasound-guided
pancreas biopsy is otherwise considered the gold stand-
ard for the diagnosis of an allograft dysfunction.
Unfortunately, hyperglycemia is a late marker of chronic
graft rejection. Although plasma glucose has high specifi-
city (90 % to 95 %), it is the least sensitive marker of rejec-
tion [31]. Hence, identification of the subjects at risk of
returning to the diabetic state due to graft loss or any
other cause is difficult and often delayed. Consequently,
appropriate treatment becomes unfeasible.
Several tests have been proposed to identify patients at
high risk for all-cause pancreatic graft failure. Slight al-
terations in glucose metabolism seem to appear earlier
and might be predictive of pancreatic graft failure.
Pfeffer et al. performed OGTT 1.7 years after SPK
transplantation on average and showed that impaired
glucose tolerance predicted risk of graft failure in
10 years [32]. Battezzati et al., taking blood samples at
2 h intervals for plasma glucose, serum insulin, and C-
peptide levels, reported that mean 24-h glucose greater
than 127 mg/dL at 1 year posttransplantation was the
best predictive index of return to a diabetic state [33].
The intravenous glucose tolerance test and the arginine-
induced insulin secretion test have also been used as
rejection markers [34, 35]. In islet transplantation pa-
tients, glucose variability and a higher frequency of
glucose levels above 140 mg/dL determined by the
continuous glucose monitoring system (CGMS) have
proved useful early indicators of graft dysfunction [36].
We have also demonstrated that 72 h mean glucose
measured by CGMS in PTX patients with normal oral
glucose tolerance was associated with chronic rejection
in a 5 year follow-up [37]. Recently, Hiratsuka et al.
have described the utility of peripheral plasma fasting
Table 1 Related risk factors for diabetes mellitus following
pancreas transplantation
• Donor: older age and high body mass index
• Surgical procedure: extensive manipulation of the graft and long
ischemic period
• Recipient: higher body mass index and posttransplant weight gain;
donor age, hepatitis C virus and donor-positive with recipient-
negative CMV status
• Type of pancreas transplantation: pancreas transplantation alone
and pancreas after kidney transplantation
• Immunosuppressive regimen: prolonged use of glucocorticoids and
use of tacrolimus
• Follow-up: number of acute rejection episodes, loss of the kidney graft
in pancreas-kidney transplantation, and long duration of the transplant
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serum C-peptide response to 1 mg of glucagon intra-
venously to predict insulin-free treatment [38]. How-
ever, further studies are warranted, since biochemical
parameters and imaging tools still lack diagnostic ac-
curacy to detect early graft failure, especially for PTA
and PAK.
In SPK recipients, serum creatinine levels have been
used to diagnose rejection, since kidney graft rejection
usually precedes or is concurrent with rejection of the
pancreas graft [19].
Urinary amylase levels can be monitored in pancreas
recipients with bladder-drained exocrine secretions
[39, 40]. An analysis result of a 12-h or 24-h urine col-
lection in which amylase levels have declined 50 % or
more from baseline suggests rejection or pancreatitis.
Serum amylase and lipase levels provide additional
means for following pancreas function, especially in
the case of enterically drained grafts. However, they
lack the sensitivity and specificity of urinary amylase
measures [4]. Long-term graft survival is greater for
SPK vs PAK or PTA transplants, which partly explains
the decrease in the number of these two last transplant
modalities in the past decade [41]. Indeed, in SPK the
pancreas and kidney are usually obtained from the
same deceased donor and, therefore, changes in kidney
function can be used to monitor whether rejection is
occurring at either organ.
Table 2 summarizes the recommended tests for identi-
fying patients at risk for pancreatic graft dysfunction.
Management
Strict glycemic control is the cornerstone of therapy,
which can preserve residual β-cell function and eventu-
ally recover it when glucotoxicity is corrected. Blood
glucose levels should be less than 110 mg/dL before
meals and less than 180 mg/dL postprandial [42].
Insulin therapy is generally preferred because of its su-
perior results in controlling diabetes, in addition to be-
ing more predictable and rapidly titrated. Insulin therapy
is mandatory in the setting of ketoacidosis or metabolic
decompensation with unintended weight loss. Further-
more, insulin should be used when hyperglycemia de-
rives from rejection or other causes of graft failure.
Further, insulin therapy is mandatory when hypergly-
cemia derives from rejection or other causes of graft
failure. Despite extensive clinical experience with a var-
iety of insulin types, no prospective studies have ad-
dressed the relative efficacy of specific insulin regimens
for treating posttransplant diabetes [42].
When the cause of hyperglycemia is new-onset type 2
diabetes, oral agents can be used, although this has not
been clearly defined for PTX. They should be attempted
in patients with mild hyperglycemia with preserved/ro-
bust c-peptide. Metformin improves insulin sensitivity,
most notably in the liver. Given the risk of metformin-
induced lactic acidosis, this agent is contraindicated for
patients with severe renal or hepatic dysfunction. Sulfo-
nylureas stimulate insulin secretion and can be an op-
tion. However, these drugs are associated with an
increased risk of hypoglycemia and can also contribute
to β-cell exhaustion. Thiazolidinediones, which primarily
target insulin resistance at the level of skeletal muscles
and adipocytes, have been evaluated as a potential thera-
peutic option and seem to be a safe and effective treat-
ment. Special attention must be given to the side effects
of thiazolidinediones, such as weight gain, hepatotox-
icity, edema, cardiac failure, and increased fracture risk.
Agonists of GLP-1 and oral dipeptidyl peptidase inhibi-
tors have not been consistently investigated and thus
cannot be recommended, although they might have a
positive effect by stimulating insulin secretion in trans-
plant recipients [43].
Although current clinical evidence is largely anec-
dotal, tailoring of immunosuppression should be con-
sidered in patients with poorly controlled diabetes
despite therapeutic lifestyle changes and pharmacologic
interventions. In this context, therapeutic options in-
clude reduction in corticosteroid and/or calcineurin in-
hibitors dose, and conversion from tacrolimus to
cyclosporine or sirolimus [44, 45].
Steroid avoidance or withdrawal for PTX patients has
been a matter of debate. A recent review by Montero
et al. [46] concluded that the available data, including
randomized controlled trials, are still insufficient to
firmly infer on the harms and benefits of steroid with-
drawal in pancreas transplantation. A study by Amodu
et al. [47] showed that steroid maintenance is not associ-
ated with the risk of death or graft failure although
increasing the risk of infectious complications.
Hyperlipidemia after pancreas transplantation
Lipid metabolism disorders
Hyperlipidemia after solid organ transplantation occurs in
60 % to 80 % of recipients of immunosuppressive therapy
[48]. High triglycerides and low density lipoprotein choles-
terol (LDL-c) levels are two of the most important lipid
disorders found in those patients. Combined hyperlipid-
emia is also common. Many risk factors can contribute to
the development of dyslipidemia after PTX, such as older
Table 2 Tests for identifying pancreas graft dysfunction
• Urinary amylase levels (only for bladder- drained transplants)
• Serum amylase and lipase levels
• Fasting glucose levels (consider OGTT if >100 mg/dl)
• A1C
• Creatinine (in SPK patients)
• Duplex sonographic scanning of the allograft (when thrombosis
and/or rejection are suspected)
• Ultrasound- guided biopsy (gold standard for rejection)
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age, obesity, posttransplantation weight gain, pretrans-
plantation hyperlipidemia, male gender, graft dysfunction,
proteinuria, new-onset diabetes, prednisone dosage, and
the type of immunosuppression regimen (Table 3).
Sirolimus has been found to be associated with greater
increases in triglycerides and cholesterol, although tacro-
limus and cyclosporine also have deleterious effects on
lipid metabolism [5, 10].
The majority of PTX patients have preexisting dys-
lipidemia, since they are generally poorly controlled
diabetes patients, most of them with advanced ne-
phropathy. Compared to preoperative levels, patients
who underwent SPK experience improvements in their
lipid profile, while those submitted to PTA remain
with stable lipid levels [49]. Patients who underwent
PTA exhibit similar lipid levels to SPK patients post-
transplantation, which suggests that the contrasting
clinical course seen between these two groups is attrib-
utable to preoperative lipid profile differences [26].
Relative to PTA patients, SPK patients have signifi-
cantly lower levels of LDL-c and use significantly fewer
lipid-lowering medications [50]. Portal venous instead
of systemic venous drainage of the pancreas allograft
does not seem to impact lipid metabolism in the long-
term follow-up [17]. Steroid withdrawal regimens have
been related to lower prevalence of hyperlipidemia after
PTX [51].
Qualitatively, a persisting profile of potentially athero-
genic alterations in lipoprotein lipase, cholesteryl ester
transfer, and lipoprotein composition has been reported
after PTX [52]. However, the findings and interpretation
of those data have been questioned by others [53].
Evaluation
In the first 3 months following PTX, lipid levels are
quite unstable because of high doses of immunosuppres-
sive drugs [54]. After that, levels usually stabilize during
the first year posttransplantation. It is important to avoid
misleading situations when interpreting the results, such
as acute stress conditions and secondary causes of
dyslipidemia.
Monitoring lipid profile at least every 6 months fol-
lowing transplantation is advisable.
Management
Due to the high incidence of atherosclerotic disease
events and the absence of specific studies, PTX patients
should be considered high risk and treated to maintain
LDL-c <100 mg/dl, according to published guidelines for
kidney transplant patients [55].
A diet-oriented approach should be the first line treat-
ment in hyperlipidemia [56]; changes in the immunosup-
pression regimen should also be considered. Tacrolimus
appears to have fewer adverse effects on lipids than cyclo-
sporine, which is not explained by concomitant steroid ad-
ministration. Cross-over studies with renal transplant
patients have shown improvement in lipid profile after
conversion from cyclosporine to tacrolimus [57, 58].
Statins are considered the cornerstone of drug ther-
apy in posttransplantation hypercholesterolemia. The
outcomes and benefits of statins based on heart and
kidney clinical studies provide a solid rationale to sup-
port their use in organ transplantation. Furthermore,
statins can potentially exert cholesterol-independent
immunosuppressive effects [59]. Use of statins in PTA
patients may lead to improved outcomes. Whether this
is due to cardiovascular protection or other factors un-
related to lipid lowering remains unclear [60].
Similarly to kidney transplant, statin treatment has un-
certain effects on overall mortality, stroke, kidney func-
tion, and toxicity outcomes in PTX recipients. Further
studies would improve our knowledge of the benefits
and harms of statin treatment regarding cardiovascular
events in this clinical setting [61].
Since statins can cause hepatotoxicity, it is important
to monitor liver function after statin introduction. More-
over, we should be cautious about the myotoxic effects
of statins and the risk of rhabdomyolysis due to inter-
action with drugs that inhibit the cytochrome P450 iso-
enzyme and thus increase statin levels [62]. Regarding
associations between statins and tacrolimus, animal
studies have shown a pronounced interaction, similar
to that described for cyclosporine. Not all statins are
metabolized by the same enzyme; therefore, they ex-
hibit a different drug interaction and safety profile [63].
Statin-induced dysglycemia is another concern that has
recently been described in kidney transplants [64]. The
choice of a statin should be based on individual patient
requirements and adapted according to treatment re-
sponse. Pravastatin and fluvastatin have been consid-
ered the safest statins to be used in transplanted
patients [65]. However, given their low potency, a high-
potency statin may be necessary in patients with signifi-
cant dyslipidemia [66, 67].
Table 3 Risk factors contributing to the development of
dyslipidemia following pancreas transplantation
• Older age
• Obesity/Overweight







• Immunosuppressive agents: sirolimus (particularly), tacrolimus,
cyclosporine
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Concerning hypertriglyceridemia, fibrates should be
used cautiously, since they may induce renal dysfunction.
Gemfibrozil seems to be devoid of this side-effect [68].
Interestingly, in the Fenofibrate Intervention and Event
Lowering in Diabetes (FIELD), fenofibrate reduced albu-
minuria and slowed estimated renal function loss over
5 years, despite initially and reversibly increasing plasma
creatinine. Confirmatory studies are merited [69].
Bone diseases following pancreas transplantation
Calcium and bone metabolism disorders
Bone complications are another major source of late
morbidity for PTX patients. Fractures after SPK trans-
plant are common: 45 to 49 % within the first 2 years,
which is one of the highest fracture rates reported for
any organ transplant [70]. Cortical osteoporosis is
prevalent in SPK recipients at the time of transplant-
ation and shows early progression after transplantation
[71]. Over the long term, bone densitometry values and
fracture risk seem to stabilize or improve, especially in
steroid sparing protocols and/or aggressive osteoporosis
treatment [71, 72].
The disturbances in bone and mineral metabolism ob-
served after transplantation are largely determined by
preexisting factors at the time of transplantation (ad-
vanced age, female gender, long duration of pretrans-
plant kidney failure, history of pretransplant fracture)
and by factors inherent to the transplant status, such as
kidney function and use of immunosuppressive agents
[73, 74] (Table 4).
Compared to PTA recipients, kidney transplant recipi-
ents have the disadvantage of presenting for transplant-
ation with preexisting osteodystrophy, which is difficult
to predict from routine laboratory or radiologic investiga-
tions and it may persist, improve, or worsen after trans-
plantation [75]. Interestingly, SPK has been associated
with a significant 31 % reduction in fracture risk com-
pared to kidney alone transplantation in men with type 1
diabetes after adjustment for fracture covariates [76]. It is
not known whether the apparent benefit of SPK is due to
improved bone strength or fewer falls observed with the
restoration of euglycemia. Furthermore, a recent study by
Rocha et al. [77] showed that, in SPK patients followed for
at about 3 years, a gain in BMI was significantly predictive
of bone mass improvement whereas an increasing in
serum levels of alkaline phosphatase was significantly
associated with a decrease in the same parameter.
After kidney transplantation, many laboratory features
of chronic kidney disease improve; however, abnormally
high or low bone turnover rates have been reported in
bone biopsy studies [78, 79].
Corticosteroids exacerbate bone loss by suppressing
osteoblastic activity and activating osteoclastic resorp-
tion. Calcineurin inhibitors also have direct negative ef-
fects on bone [80–82]. Factors such as hypogonadism,
vitamin D deficiency, adynamic bone disease, previous
or ongoing parathyroid disease, previous uncontrolled
diabetes, and thyroid function abnormalities can also
contribute to bone loss [19]. Persistently increased PTH
concentrations can be found in as many as 75 % of pa-
tients at 1 year posttransplantation; this is largely due to
failure of the enlarged glands to involute. Elevated
FGF23 levels and decreased Klotho expression in the
parathyroid gland may play a role in the pathogenesis of
hyperparathyroidism after kidney transplantation [83]. A
major determinant of persistent posttransplant hyper-
parathyroidism is its severity at the time of transplant-
ation, corresponding to pretransplantation PTH levels
[84, 85]. Persistent hyperparathyroidism is a major risk
factor for fractures after kidney transplantation [86]. The
foot and ankle are the most common fracture sites after
PTX, accounting for over 50 % of the cases. This sug-
gests that preexisting diabetes-related deformities could
be an etiologic factor. Charcot neuroarthropathy has
been diagnosed in 4.6 % of SPK recipients during the
first year posttransplantation [87, 88]. In addition, a var-
iety of other anatomic sites are affected [89].
Evaluation
No clinical trial data to inform clinical recommenda-
tions for bone disease in PTX patients are available.
Most data is limited to before-after data or registry
studies. In view of this, guidance for renal transplant-
ation patients is taken as a reference, although it needs
to be applied cautiously [55].
Close monitoring of serum calcium, phosphate, 25-
hydroxy-vitamin D (25 OH-D), and PTH concentrations
are recommended for SPK and PAK recipients [19].
Bone mineral density should be measured in the first
3 months after transplantation, when patients have a cal-
culated clearance of creatinine above 30 mL/min, and
then repeated on a regular basis [55]. The work-up
should also include periodical determination of thyroid
and sex hormone status in eligible populations [4]. Bio-
markers of bone turnover could be useful in individual-
izing therapy to prevent or treat bone loss after
transplantation [90]. For PTA recipients, evaluation
should be done considering the presence of other
Table 4 Factors related to bone and mineral metabolism
disturbances following pancreas transplantation
• Preexisting: older age, female gender, long duration of pretransplant
kidney failure, history of pretransplant fracture, severity of
hyperparathyroidism secondary to kidney disease
• Inherent to transplant status: kidney function, use of
immunosuppressive agents (especially glucocorticoids and
calcineurin inhibitors)
• Other factors commonly observed after transplantation:
hypogonadism, vitamin D deficiency, persistent parathyroid disease,
thyroid abnormalities
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fracture risk factors such as peripheral neuropathy, poor
muscle strength, balance impairment, visual acuity re-
duction, and propensity to falls.
Management
Vitamin D deficiency and insufficiency should be cor-
rected by using treatment strategies recommended for
the general population to achieve a serum 25 OH-D
concentration of at least 20 ng/mL to prevent and treat
osteometabolic diseases [55]. Low 25 OH-D has been in-
dependently associated with an increased risk of all-
cause mortality in kidney transplantation [91]. Pleotropic
effects of vitamin D, such as immune response regula-
tion, and protective effects from cardiovascular disease,
cancer, and infections seem to be very attractive to the
transplanted population. However, more solid data are
needed to confirm this and to set the optimal level of
serum Vitamin D supplementation in order to attain the
best clinical outcome [92]. Calcium supplementation
(500 mg elemental calcium daily) appears to lower bone
resorption after transplantation and should be routinely
prescribed—especially in regimens with high doses of
immunosuppressive drugs [93]. Calcium dietary intake
of at least 1 g daily should also be advised.
In patients with established osteoporosis (presence of
densitometric osteoporosis or fractures associated with
osteopenia), anti-resorption therapy, usually with
bisphosphonates orally or intravenously, is warranted
[90, 94]. Bisphosphonates may also be beneficial to pre-
vent bone loss after transplant, although this needs to be
more clearly established.
In patients with persistent hyperparathyroidism after
transplantation, calcitriol may provide additional benefits
in reducing bone loss [94]. A calcium sensor blocker
(Cinacalcet) has not yet been approved for use in trans-
planted patients and evidence of its safety in this clinical
setting is still incomplete. In refractory and persistent
cases of hyperparathyroidism, parathyroidectomy should
be considered [95].
Other endocrine and metabolic diseases
Thyroid diseases are common in the general population
and, therefore, can be often observed in the pancreas
transplanted population. Furthermore, patients with type
1 diabetes show increased incidence of autoimmune thy-
roid diseases. However, no relationship between pan-
creas transplantation and thyroid disesases has been
described. Thus, screening and management of thyroid
diseases in pancreas transplanted patients is not different
from the general population.
Hypogonadism in men and women have been reported
before and after pancreas transplantation, mainly in
those patients with SPK and probably due to the effects
of the end stage renal disease in the hypothalamic-
gonadotroph axis function. Immunosupressive drugs
may play a role in these disorders. However, in the ma-
jority of the cases, gonadal function actually recovers
after transplantation [96]. Glucocorticoid metabolism
alterations may occur in transplanted patients and are
related to its chronic use to prevent organ rejection.
These patients should be advised to increase or re-
assume glucocorticoid therapy during stress to avoid
adrenal insufficiency.
Conclusions
Disturbances in the metabolism of carbohydrates, lipids,
and bone mineral are prevalent problems observed in
the follow-up of PTX patients. In addition to causing
morbidity, such disturbances can indirectly increase the
risk of death associated with cardiovascular diseases and
fractures. Previous recipient-related and donor-related
factors and others inherent to the transplant act together
in the pathogenesis of these abnormalities. Early recog-
nition of such disturbances is the key to timely treat-
ment; however, adequate tools to achieve this goal are
frequently lacking. Further studies are needed to define
the best approach for PTX patients.
PTX is a technically demanding procedure which is as-
sociated with the above-mentioned abnormalities in the
endocrine system beyond infectious and rejection com-
plications. Furthermore, patient follow-up is complex
due to multiple interfering factors, where immunosup-
pressive drugs play an important role. Therefore, despite
the good outcomes recently achieved in centers with a
specialized transplantation unit as well as recent ad-
vances to the field, PTX should still be considered the
last resort treatment in patients whose diabetic compli-
cations have become life-threatening or enough burden-
some to be maintained with the current available
diabetes treatment.
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